Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSGLP-1 drugs are known to prevent strokes. In 209,180 records, the people taking one who had a stroke anyway arrived with milder strokes, fewer complications, and lower 30-day death than matched non-users.
A rationally designed peptide called X1-3 killed MRSA and carbapenem-resistant gut bacteria on its own, then made the beta-lactam antibiotics those bugs had defeated work again by disabling the NDM and PBP2a resistance enzymes. It is a dish-and-mouse result from Northwest A&F University, not yet a drug.
Cigarette smoke shreds the lung's elastic scaffold into short peptides, and a Guangzhou Medical University study finds those fragments actively block the stem-cell handoff that rebuilds alveoli. An experimental peptide that neutralizes them partly restored repair in smoke-exposed mice.
In 52,212 obese non-diabetic adults, pairing a GLP-1 injection with an SGLT2 pill cut irregular heartbeats about 18 percent over five years, almost all of it atrial fibrillation. An early bump in a dangerous ventricular rhythm faded by year five.
Turning the GIP receptor on suppresses appetite through the brainstem. Blocking it boosts GLP-1 weight loss through the hypothalamus. A Cambridge mouse study maps the field's most contradictory result to two different brain regions, which means tirzepatide and MariTide were never really answering the same question.
In nearly a million people with type 2 diabetes, SGLT2 inhibitors were tied to fewer osteoarthritis diagnoses than GLP-1 drugs. The edge vanished at the endpoint that counts, knee and hip replacement.
DMS-DA6, a dermaseptin from the Mexican leaf frog, cleared actinomycetoma in mice on eight injections while linezolid took about fifty-six doses. It killed bacteria and retuned the immune response at once.
Temporin-GHaR6R, an antimicrobial peptide from frog skin, cut how often mice developed an MS-like disease when given before onset. It worked by steering brain immune cells out of their inflammatory state and fusing their fragmented mitochondria back together.
Alpha-1 antitrypsin ran higher in bacterial community-acquired pneumonia than viral, independent of CRP, with an AUC of 0.803. Its shed C-terminal peptides split further: C37 leaned bacterial, C40 leaned viral.
Pep19-2.5, built to soak up bacterial toxins, turns out to shut down the NLRP3 inflammasome from inside the cell. In mouse airways it cut IL-1 beta and eosinophils and improved lung function.
Intranasal vasopressin lowered voluntary ethanol intake in mice without moving blood pressure. Blocking any one of three receptors it lands on (V1a, V1b, or the oxytocin receptor) undid the effect, and social housing recruited a different receptor than solitary housing.
The first registered review of GLP-1 receptor agonists in multiple sclerosis found the drugs reliably reduced disease severity in mice but trimmed only weight in patients, with no change in disability or relapse across barely a hundred people.
A meta-analysis of 20 studies and 546,668 patients found no rise in eight surgical complications for GLP-1 drug users after spine surgery, and about 50 percent higher odds of a successful bone fusion.
A pooled analysis of five studies and 1,186 people with metastatic neuroendocrine cancer found that removing the primary tumor before peptide receptor radionuclide therapy tracked with 38 percent lower progression risk (HR 0.62) and 54 percent lower death risk (HR 0.46). The authors call it an association, not proof, and name the two biases that could explain it.
Kids carrying one version of the GLP1R gene, the target Ozempic hits, were more insulin-sensitive and made less GLP-1, before any drug. An association, not a prescription.